The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...
Nuvation Bio (NYSE:NUVB – Free Report) had its price objective upped by HC Wainwright from $10.00 to $11.00 in a research ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...
Assenagon Asset Management S.A. lessened its stake in shares of Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 70.5% during ...
A few hours after taking the Oath of Office on Monday, President Donald Trump issued an executive order purporting to ...